Results 41 to 50 of about 7,834 (208)
BMC Cancer, 2020 Background PARP inhibitors niraparib and talazoparib are FDA approved for special cases of breast cancer. PARP is an interesting repair protein which is frequently affected in cancer cells.
Verena Weigert +6 more
doaj +1 more source
BMN673 sensitizes rhabdomyosarcoma tumors to irradiation in vivo [PDF]
, 2020 Bone and soft tissue sarcomas are mesenchymal tumors that occur rarely in adults, representing only 1% of total malignancies, but comprise up to 13% of malignant tumors in children.1 Rhabdomyosarcoma, a soft tissue sarcoma that commonly affects children,
Jacob, Connor
core
E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling [PDF]
, 2015 Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.) have demonstrated clinical proof of concept for cancer treatment.
Chang, Paul
core +1 more source
Niraparib in ovarian cancer. results to date and clinical potential [PDF]
, 2017 Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both ...
Benedetti Panici, Pierluigi +5 more
core +1 more source
Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
Frontiers in Oncology, 2023 Colorectal cancer (CRC) is currently one of the most common tumor types diagnosed worldwide. In the early stages, the disease responds well to surgical and chemotherapeutic treatment, but in the later stages when therapeutic options are exhausted ...
Elizaveta Polyanskaya +14 more
doaj +1 more source
Frontiers in Immunology, 2022 BackgroundThe benefits of talazoparib compared with conventional chemotherapy in HER2-negative advanced breast cancer (ABC) remain unclear.MethodsPatients older than 18 years, with a deleterious germline BRCA1/2 (gBRCA1/2) mutated, metastatic, or locally
Ning Wang, Xiaopeng Yu
doaj +1 more source
Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
Cells, 2022 Inhibitors (PARPi) of poly(ADP-ribose-)polymerase-1 (PARP1) are used in antitumor therapy; their cytotoxicity correlates with the efficiency of PARP1 trapping in cell chromatin.
Natalya Maluchenko +4 more
doaj +1 more source
Computational approaches to identify genetic interactions for cancer therapeutics [PDF]
, 2017 The development of improved cancer therapies is frequently cited as an urgent unmet medical need. Here we describe how genetic interactions are being therapeutically exploited to identify novel targeted treatments for cancer.
Benstead-Hume, Graeme +2 more
core +2 more sources
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design [PDF]
, 2022 PARP inhibitor; Androgen receptor; EnzalutamideInhibidor de PARP; Receptor d'andrògens; EnzalutamidaInhibidor de PARP; Receptor de andrógenos; EnzalutamidaPARP inhibitors in combination with androgen receptor-targeted therapy have demonstrated potential ...
Agarwal, Neeraj +5 more
core +1 more source